March 29, 2018
Shanghai, China
Finnegan’s Shanghai Office cordially invites you to attend the Advanced Intellectual Property Seminar Program series. This program features Finnegan attorneys Tom Irving, Paul Browning, and Yieyie Yang discussing Recent Developments in United States (U.S.) Life Sciences Patent Law.
Tom Irving, with more than 40 years of experience in the field of intellectual property law, will discuss legal developments in the area of life science patent prosecution, due diligence, and inter partes reviews (IPRs). In particular, Tom will discuss strategies for securing U.S. patents with valid, enforceable claims designed to withstand challenges in both the courts and in USPTO post-grant proceedings. He will also address analyzing patent claims in a due diligence from the viewpoints of both the Target and Suitor and potential solutions to any issues found during that analysis. Finally, he will share ideas about what a patent owner should do if drawn into an inter partes review (IPR) proceeding.
Paul Browning, Ph.D., focuses on patent litigation and appeals, primarily in the chemical and pharmaceutical areas, and has led teams as first chair at trial, at Markman proceedings, and on appeal. He will discuss recent developments in U.S. patent law in the life science area and the impact of those changes on litigation practice. Among other things, he will discuss changes to U.S. venue law that affect where patent suits may be litigated in the United States, as well as recent judicial decisions that impact patent validity challenges in U.S. courts. Finally, he will provide guidance for Chinese companies that are contemplating or expecting litigation in U.S. courts.
Yieyie Yang, Ph.D., has experience in Abbreviated New Drug Application (ANDA) litigation, and prosecution, due diligence, IPR, and litigation of biological product patents. She will discuss the recent case law development regarding biosimilars litigation under the Biologics Price Competition and Innovation Act (BPCIA), including the timing of filing a declaratory judgment action, the exchange of information, asserting patents in the exchanged patent list, and the 180-day notice. She will also discuss the written description requirement for antibody patents from the perspectives of prosecution, IPR, and litigation.
Moderator:
Ningling Wang
Speakers:
Tom Irving
Paul Browning, Ph.D.
Yieyie Yang, Ph.D.
Agenda:
13:00 - 13:30 Registration
13:30 - 13:40 Welcome Remarks
13:40 - 14:50 Patent Prosecution, Due Diligence, and IPRs
14:50 - 15:10 Coffee Break
15:10 - 16:20 Patent Litigation
16:20 - 17:00 Patent Prosecution and IPRs related with Large Molecules
17:00 - 17:30 Questions and Answers
Date:
Thursday, 29 March 2018
Venue:
The Ritz-Carlton Shanghai Pudong
Amber Room, 3rd Floor
Shanghai IFC, 8 Century Avenue,
Lujiazui, Pudong New Area
Shanghai 200120
Register:
RSVP by 23 March 2018 to ipeventshanghai@finnegan.com.
Space is limited—by invitation only.
Hybrid Conference
2024 California Intellectual Property Law Institute
October 21-22,2024
San Francisco
Conference
4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
October 8-24, 2024
Virtual
Hybrid Conference
2024 Patent Law Institute: Critical Issues & Best Practices
September 30 - October 1, 2024
New York
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.